Biomm S.A. operates as a biotechnology company in Brazil. The company offers insulin products for the treatment of diabetes, including AFREZZA, a human insulin powder for inhalation; GLARGILIN, a glargine insulin; WOSULIN N and WOSULIN R; Lifepen G, a reusable insulin injection pen; and Biopemm, a reusable insulin delivery device for diabetic patients. It also provides Bevyx for the treatment of metastatic colorectal cancer; HERZUMA for the treatment of early-stage and metastatic breast cancer and metastatic gastric cancer with HER2-positive tumors; GHEMAXAN, an anticoagulant for the treatment of deep vein thrombosis and pulmonary embolism, unstable angina, and acute myocardial infarction; and RANIVISIO for treating vision problems related to abnormal blood vessel growth or fluid buildup in the retina. The company was incorporated in 2001 and is based in Nova Lima, Brazil.
Frequently asked questions
What sector does Biomm S.A (BIOM3) operate in?
Biomm S.A belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Biomm S.A (BIOM3) current stock price?
As of the latest data, Biomm S.A stock price is R$5.45, with a previous close of R$5.69. Biomm S.A lost -R$0.24 in the last trading session, representing a -4.22% loss.
What is Biomm S.A (BIOM3) current market capitalization?
Biomm S.A market cap is approximately 745.85 million.
What is Biomm S.A (BIOM3) Earnings Per Share (EPS)?
The trailing EPS is R$0.12.
What is Biomm S.A (BIOM3) Price-to-Earnings (P/E) ratio?
Biomm S.A current P/E ratio is 45.42.
What is Biomm S.A (BIOM3) EBITDA?
Biomm S.A EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 19.65 million.
Does Biomm S.A (BIOM3) pay dividends?
No. Biomm S.A does not pay a dividend.
What is Biomm S.A (BIOM3) beta (volatility) score?
Biomm S.A has a beta of 0.441, indicating lower volatility than the overall market.
